Revolutionize binding for the future of immunotherapy: A virtual Avidion demo

90% of immuno-oncology drugs entering Phase I clinical trials fail, due to a poor predictive value of current preclinical assays. To solve this, scientists and drug developers are turning to Cell Avidity, the total binding strength between cells, to better predict therapeutic efficacy.​

​Join us for an exclusive virtual demonstration of Avidion, the next generation of Cell Avidity technology. This session isdesigned for researchers and groups who understand the "why" of avidity but want to see the "how." ​

We will take you inside the instrument to explore the automated workflow, preview our intuitive software interface, and show real-world customer proof that validates its predictive power. See how Avidion transforms complexcellular interactions into actionable insights with push-button simplicity.​

​

We know your time is valuable, that's why we designed this 30-minute intensive session specifically for researchers who need to seethe technology in action. Don’t miss your chance to talk directly with LUMICKS scientists and product managers. See the future of cell interaction analysis from your desk.​